 This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy SBRT used as a window of opportunity treatment before nivolumab in patients with metastatic squamous and non-squamous non-small cell lung carcinoma NSCLC. In situ gene therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase ADVHSV-tk plus Valacyclovir therapy. 